S D Shafran|G Di Perri - JoVE Visualize

Showing results (101-110 of 146) with videos related to

Pageof 15

Sort By:

Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|June 9, 2022

Sex-specific fat mass ratio cutoff value identifies a high prevalence of cardio-metabolic disorders in people living with HIVM Barale, M Massano, F Bioletto, et al.

HIV Clinical Trials|March 11, 2011

Maraviroc can improve lipid profiles in dyslipidemic patients with HIV: results from the MERIT trialA MacInnes, A Lazzarin, G Di Perri, et al.

Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|November 10, 2016

Blood Brain Barrier Impairment in HIV-Positive Naïve and Effectively Treated Patients: Immune Activation Versus AstrocytosisA Calcagno, A Romito, C Atzori, et al.

Lancet (London, England)|December 23, 1989

Nosocomial epidemic of active tuberculosis among HIV-infected patientsG Di Perri, M Cruciani, M C Danzi, et al.

International Journal of Antimicrobial Agents|January 29, 2020

Serum Trimethylamine-N-oxide Concentrations in People Living with HIV and the Effect of Probiotic SupplementationC Montrucchio, A De Nicolò, G D'Ettorre, et al.

The Journal of Antimicrobial Chemotherapy|March 24, 2017

Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failureA Calcagno, N Pagani, A Ariaudo, et al.

British Journal of Clinical Pharmacology|February 15, 2018

Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administrationA Calcagno, C Pinnetti, A De Nicolò, et al.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 19, 1999

A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complexF M Gordin, P M Sullam, S D Shafran, et al.

The Pharmacogenomics Journal|November 9, 2018

Tenofovir disoproxil fumarate discontinuation for renal outcomes: any room for treatment personalization?A Calcagno, M Fiumanò, D Zugna, et al.

Journal of Neurovirology|July 7, 2017

Detectable cerebrospinal fluid JCV DNA in late-presenting HIV-positive patients: beyond progressive multifocal leukoencephalopathy?S Mornese Pinna, E Scarvaglieri, M G Milia, et al.

Pageof 15

Showing results (101-110 of 146) with videos related to

Sort By:

Pageof 15

Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|June 9, 2022

Sex-specific fat mass ratio cutoff value identifies a high prevalence of cardio-metabolic disorders in people living with HIVM Barale, M Massano, F Bioletto, et al.

HIV Clinical Trials|March 11, 2011

Maraviroc can improve lipid profiles in dyslipidemic patients with HIV: results from the MERIT trialA MacInnes, A Lazzarin, G Di Perri, et al.

Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|November 10, 2016

Blood Brain Barrier Impairment in HIV-Positive Naïve and Effectively Treated Patients: Immune Activation Versus AstrocytosisA Calcagno, A Romito, C Atzori, et al.

Lancet (London, England)|December 23, 1989

Nosocomial epidemic of active tuberculosis among HIV-infected patientsG Di Perri, M Cruciani, M C Danzi, et al.

International Journal of Antimicrobial Agents|January 29, 2020

Serum Trimethylamine-N-oxide Concentrations in People Living with HIV and the Effect of Probiotic SupplementationC Montrucchio, A De Nicolò, G D'Ettorre, et al.

The Journal of Antimicrobial Chemotherapy|March 24, 2017

Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failureA Calcagno, N Pagani, A Ariaudo, et al.

British Journal of Clinical Pharmacology|February 15, 2018

Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administrationA Calcagno, C Pinnetti, A De Nicolò, et al.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 19, 1999

A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complexF M Gordin, P M Sullam, S D Shafran, et al.

The Pharmacogenomics Journal|November 9, 2018

Tenofovir disoproxil fumarate discontinuation for renal outcomes: any room for treatment personalization?A Calcagno, M Fiumanò, D Zugna, et al.

Journal of Neurovirology|July 7, 2017

Detectable cerebrospinal fluid JCV DNA in late-presenting HIV-positive patients: beyond progressive multifocal leukoencephalopathy?S Mornese Pinna, E Scarvaglieri, M G Milia, et al.

Pageof 15